UK cancer biomarker market is expected to grow at a CAGR of around 11.7% during the forecast period. The major factor that are increasing the market are high prevalence of cancer in the region, well-developed healthcare infrastructure and presence of major market player in the nation. Additionally, as the country have developed economy, per capita healthcare investment from government and public is higher than other developing nation and hence significant research can be observed in the near future.
To Request a Sample of our Report on UK Cancer Biomarker Market: https://www.omrglobal.com/request-sample/uk-cancer-biomarker-market
The healthcare expenditure of the UK is more than $25,000 million as compared to Germany and France. This is one of the major factors that tends to rise the UK cancer biomarker market. AS per OECD, the prevalence of cancer in the UK is approx. 225 per 100,000 people in 2011 which is estimated to reduce only to 214 per 100,000 people in 2017. The incidences of cancer patients in the UK has been very frequent previously.
The increasing integration of healthcare with technology is augmenting the UK cancer biomarker market. There are various procedures that are being uniquely available at UK treatment centers. For instance, the Clatter Bridge Cancer Centre is one of the first two hospitals in the UK to offer dose painting radiotherapy to patients. The technique is suitable for patients with a higher density of cancer cells, which have not spread from the prostate gland. This applies to 30- 50% of all prostate cancer cases. While an equal amount of radiation is delivered by the standard radiotherapy on prostate, in dose painting radiotherapy, MRI scans or PET CT scans first identify areas of the prostate which is more affected.
Further, during the year 2016/2017 the Cancer Research UK supported the research based on cancer worth $490.22 million. On the lung cancer research $55.11 million was spent whereas an amount of $44.06 million was spent in the research of colon and rectal cancer. For, breast cancer $ 41.65 million was spent on the research. The funding in the research is expected to motivate the UK market of cancer biomarker. Thus, such contributions by the government organizations is expected to further drive the UK cancer biomarker market.
(Get 15% Discount on Buying this Report)
A full Report of UK Cancer Biomarker Market is Available @ https://www.omrglobal.com/industry-reports/uk-cancer-biomarker-market
UK Cancer Biomarker Market Segmentation
By Biomarker Type
- Genetic Biomarker
- Protein Biomarker
By Cancer Type
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Other
By Applications
- Drug Discovery and Development
- Diagnosis
- Risk Assessment
- Prognostics
By Profiling Technology
- Omics Technology
- Immunoassays
- Cytogenetics
- Bioinformatics
Company Profiles
- Abbott laboratories Inc.
- Astellas Pharma Inc.
- Becton, Dickson and Co.
- Bio-Rad Laboratories, Inc.
- Danaher Corp.
- F. Hoffmann-La Roche Ltd.
- Merck and Co., Inc.
- Novartis AG
- Pfizer Inc.
- QIAGEN GmbH
- Thermo Fisher Scientific Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
